Cargando…

Management of Crohn’s disease in poor responders to adalimumab

Anti-tumor necrosis factor therapy with adalimumab is an effective therapy for the induction and maintenance of remission in moderate to severe Crohn’s disease. Although a large proportion of patients show a favorable clinical response to adalimumab, therapy failure is common. In this review, we pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Boer, Nanne KH, Löwenberg, Mark, Hoentjen, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990367/ https://www.ncbi.nlm.nih.gov/pubmed/24748811 http://dx.doi.org/10.2147/CEG.S47627

Ejemplares similares

Golimumab for the treatment of ulcerative colitis
por: Löwenberg, Mark, et al.
Publicado: (2014)

Adalimumab in Crohn’s disease
por: Van Assche, Gert, et al.
Publicado: (2007)

Adalimumab for the treatment of Crohn’s disease
por: Cassinotti, Andrea, et al.
Publicado: (2008)

Difficult-to-treat-pediatric Crohn’s disease: focus on adalimumab
por: Zeisler, Bella, et al.
Publicado: (2015)

A Meta-Analysis of Adalimumab for Fistula in Crohn's Disease
por: Fu, Yin-mei, et al.
Publicado: (2017)

Lengthening adalimumab dosing interval in quiescent Crohn’s disease patients: protocol for the pragmatic randomised non-inferiority LADI study
por: Smits, L J T, et al.
Publicado: (2020)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Efficacy of Adalimumab in Korean Patients with Crohn’s Disease
por: Sohn, Il Woong, et al.
Publicado: (2016)

Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study
por: Biemans, Vince B C, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn’s Disease Patients in Stable Remission: The Randomized Controlled LADI Trial
por: Jansen, Fenna M, et al.
Publicado: (2023)

Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

Leukocytoclastic Vasculitis Associated with Adalimumab Therapy for Crohn’s Disease
por: Xu, Lankai Cathy, et al.
Publicado: (2023)

Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

Adalimumab in the management of Behçet’s disease
por: Ueda, Atsuhisa, et al.
Publicado: (2015)

Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
por: Reinisch, Walter, et al.
Publicado: (2020)

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease
por: Faubion, William A., et al.
Publicado: (2017)

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn’s Disease: Results of the PYRAMID Registry
por: Loftus, Edward V, et al.
Publicado: (2019)

Management of inflammatory bowel disease in poor responders to infliximab
por: Guerra, Iván, et al.
Publicado: (2014)

Mesenteric Fibromatosis in Crohn's Disease as a Potential Effect of Adalimumab
por: Abdelqader, Abdelhai, et al.
Publicado: (2016)

Listeria Monocytogenes Brain Abscess in Crohn's Disease Treated with Adalimumab
por: Atsawarungruangkit, Amporn, et al.
Publicado: (2017)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Successful Treatment of Oral Crohn’s Disease by Ustekinumab
por: Jukema, Jelmer B, et al.
Publicado: (2020)

Adalimumab treatment in Crohn’s disease: an overview of long-term efficacy and safety in light of the EXTEND trial
por: Asgharpour, Amon, et al.
Publicado: (2013)

Off‐label prescriptions of drugs used for the treatment of Crohn’s disease or ulcerative colitis
por: Simsek, Melek, et al.
Publicado: (2019)

Two Brothers with Skewed Thiopurine Metabolism in Ulcerative Colitis Treated Successfully with Allopurinol and Mercaptopurine Dose Reduction
por: Hoentjen, Frank, et al.
Publicado: (2011)

Infliximab-graded challenge in a patient with Crohn’s disease and adalimumab hypersensitivity
por: Song, Christine H, et al.
Publicado: (2012)

Reversible proteinuria after adalimumab discontinuation in a patient with Crohn's disease
por: Katsanos, Konstantinos H., et al.
Publicado: (2010)

Isolated Bilateral Gastrocnemius Myositis in Crohn Disease Successfully Treated with Adalimumab
por: Vadala di Prampero, Salvatore, et al.
Publicado: (2016)

Anti–NMDAR encephalitis in a patient with Crohn disease receiving adalimumab
por: Noble, Geoffrey P., et al.
Publicado: (2018)

Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn’s disease
por: Chen, Liang, et al.
Publicado: (2022)

Adherence to and Persistence with Adalimumab Therapy among Swedish Patients with Crohn’s Disease
por: Liu, Yifei, et al.
Publicado: (2022)

CNS TB-IRIS Following Cessation of Adalimumab in an Adolescent With Crohn’s Disease
por: Christian, Elizabeth, et al.
Publicado: (2022)

Vedolizumab for Inflammatory Bowel Disease: Two‐Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry – Vedolizumab
por: Biemans, Vince B.C., et al.
Publicado: (2019)

Fulminant Herpes Simplex Hepatitis Secondary to Adalimumab in Crohn’s Disease: A Case Report
por: Goel, Kanika, et al.
Publicado: (2019)

The Effect of Early vs Delayed Initiation of Adalimumab on Remission Rates in Patients With Crohn’s Disease With Poor Prognostic Factors: The MODIFY Study
por: Mantzaris, Gerassimos J, et al.
Publicado: (2021)

Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease
por: Carlsen, Arne, et al.
Publicado: (2018)

Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease
por: Mastronardi, Mauro, et al.
Publicado: (2019)

Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease
por: Dubinsky, Marla C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tbru29png65qlvrjp6kql4s9cd